Mumbai: In a recent BSE filing, Sun Pharmaceutical Industries Limited has informed that TARO Pharmaceuticals Inc., a subsidiary of Sun Pharmaceutical Industries Limited has completed 100 percent acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million.Founded in 2009, Antibe is an Ontario,
Canada incorporated corporation based in
Ontario, Canada. It is a clinical-stage
biotechnological company developing novel
drugs primarily focusing on reducing pain and
inflammation. Consolidated revenue from operations of the Company for the previous three years is NIL.Read also: Sun Pharma arm Taro Pharma to acquire 100% stake in Antibe TherapeuticsSun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
Read also: Sun Pharma to acquire Checkpoint Therapeutics for USD 355 million